Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma

Gut

Volumn 66, Issue 1, 2017, Pages 157-167

  Li, Xiaoguang ^a   Yao, Wenbo ^a   Yuan, Ya ^a   Chen, Peizhan ^a   Li, Bin ^b   Li, Jingquan ^a,c   Chu, Ruiai ^a   Song, Haiyun ^a,c   Xie, Dong ^a,c,d   Jiang, Xiaoqing ^b   Wang, Hui ^a,c,d  

^a Chinese Academy of Sciences   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c BEIJING HOSPITAL   (China)

^d SHANGHAITECH UNIVERSITY   (China)

Author keywords

CELL BIOLOGY; CHEMOKINES; HEPATOCELLULAR CARCINOMA; IMMUNOLOGY IN HEPATOLOGY; MACROPHAGES

Indexed keywords

CCL2 PROTEIN, HUMAN; CCL2 PROTEIN, MOUSE; CCR2 PROTEIN, HUMAN; CCR2 PROTEIN, MOUSE; CHEMOKINE RECEPTOR CCR2; MONOCYTE CHEMOTACTIC PROTEIN 1;

ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, HEPATOCELLULAR; CD8+ T LYMPHOCYTE; CELL COMMUNICATION; COCULTURE; DISEASE MODEL; DRUG EFFECTS; GENE INACTIVATION; GENETICS; HUMAN; IMMUNOLOGY; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MACROPHAGE; METABOLISM; MOUSE; PREVENTION AND CONTROL; PROGNOSIS; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; TUMOR RECURRENCE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CD8-POSITIVE T-LYMPHOCYTES; CELL COMMUNICATION; CELL LINE, TUMOR; CHEMOKINE CCL2; COCULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; GENE KNOCKOUT TECHNIQUES; HUMANS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; MICE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTORS, CCR2; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 85011691504     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-310514     Document Type: Article

References (47)

1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-27.
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
3. Ryder SD, British Society of Gastroenterology. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 2003; 52 (Suppl 3): iii1-8.
4. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006; 6: 24-37.
5. Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 2013; 339: 286-91.
6. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012; 21: 309-22.
7. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141: 39-51.
8. Shirabe K, Mano Y, Muto J, et al. Role of tumor-associated macrophages in the progression of hepatocellular carcinoma. Surg Today 2012; 42: 1-7.
9. Ding T, Xu J, Wang F, et al. High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. Hum Pathol 2009; 40: 381-9.
10. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010; 22: 231-7.
11. Takanami I, Takeuchi K, Kodaira S. Tumor-associated macrophage infiltration in pulmonary adenocarcinoma: association with angiogenesis and poor prognosis. Oncology 1999; 57: 138-42. doi:12021
12. Izumi K, Fang LY, Mizokami A, et al. Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation. EMBO Mol Med 2013; 5: 1383-401.
13. Geissmann F, Manz MG, Jung S, et al. Development of monocytes, macrophages, and dendritic cells. Science 2010; 327: 656-61.
14. Leuschner F, Dutta P, Gorbatov R, et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol 2011; 29: 1005-10.
15. Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat Rev Immunol 2011; 11: 762-74.
16. Serbina NV, Pamer EG. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat Immunol 2006; 7: 311-7.
17. Roussos ET, Condeelis JS, Patsialou A. Chemotaxis in cancer. Nat Rev Cancer 2011; 11: 573-87.
18. Sahin H, Trautwein C, Wasmuth HE. Functional role of chemokines in liver disease models. Nat Rev Gastroenterol Hepatol 2010; 7: 682-90.
19. Mandrekar P, Ambade A, Lim A, et al. An essential role for monocyte chemoattractant protein-1 in alcoholic liver injury: regulation of proinflammatory cytokines and hepatic steatosis in mice. Hepatology 2011; 54: 2185-97.
20. Baeck C, Wehr A, Karlmark KR, et al. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut 2012; 61: 416-26.
21. Sierra-Filardi E, Nieto C, Domínguez-Soto A, et al. CCL2 shapes macrophage polarization by GM-CSF and M-CSF: identification of CCL2/CCR2-dependent gene expression profile. J Immunol 2014; 192: 3858-67.
22. Zhang J, Patel L, Pienta KJ. Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic. Prog Mol Biol Transl Sci 2010; 95: 31-53.
23. Qian BZ, Li J, Zhang H, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011; 475: 222-5.
24. Zhang J, Lu Y, Pienta KJ. Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J Natl Cancer Inst 2010; 102: 522-8.
25. Pienta KJ, Machiels JP, Schrijvers D, et al. Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Invest New Drugs 2013; 31: 760-8.
26. Darlington GJ, Bernhard HP, Miller RA, et al. Expression of liver phenotypes in cultured mouse hepatoma cells. J Natl Cancer Inst 1980; 64: 809-19.
27. Yang Z, Zhang L, Ma A, et al. Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations. PLoS ONE 2011; 6: e28405.
28. Horuk R. Chemokine receptor antagonists: overcoming developmental hurdles. Nat Rev Drug Discov 2009; 8: 23-33.
29. Portolani N, Coniglio A, Ghidoni S, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg 2006; 243: 229-35.
30. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4: 71-8.
31. Sica A, Porta C, Morlacchi S, et al. Origin and Functions of Tumor-Associated Myeloid Cells (TAMCs). Cancer Microenviron 2012; 5: 133-49.
32. Mizgerd JP, Molina RM, Stearns RC, et al. Gadolinium induces macrophage apoptosis. J Leukoc Biol 1996; 59: 189-95.
33. Ahmad N, Gardner CR, Yurkow EJ, et al. Inhibition of macrophages with gadolinium chloride alters intercellular adhesion molecule-1 expression in the liver during acute endotoxemia in rats. Hepatology 1999; 29: 728-36.
34. Ruffell B, Affara NI, Coussens LM. Differential macrophage programming in the tumor microenvironment. Trends Immunol 2012; 33: 119-26.
35. Chew V, Tow C, Teo M, et al. Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. J Hepatol 2010; 52: 370-9.
36. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity 2014; 41: 49-61.
37. Wood NJ. Immunotherapy: Therapeutic potential of genetically modified HBV-specific T cells for chronic HBV infection and HBV-related HCC. Nat Rev Gastroenterol Hepatol 2011; 8: 61.
38. Greten TF, Manns MP, Korangy F. Immunotherapy of HCC. Rev Recent Clin Trials 2008; 3: 31-9.
39. El-Khoueiry AB, Melero I, Crocenzi TS, et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J Clin Oncol 2015; 33 (Suppl): LBA101.
40. Kilinc MO, Gu T, Harden JL, et al. Central role of tumor-associated CD8+ T effector/memory cells in restoring systemic antitumor immunity. J Immunol 2009; 182: 4217-25.
41. Lesokhin AM, Hohl TM, Kitano S, et al. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res 2012; 72: 876-86.
42. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015; 348: 56-61.
43. Waidmann O, Köberle V, Bettinger D, et al. Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma. J Hepatol 2013; 59: 769-79.
44. Capece D, Fischietti M, Verzella D, et al. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed Res Int 2013; 2013: 187204.
45. Tang X, Mo C, Wang Y, et al. Anti-tumour strategies aiming to target tumour-associated macrophages. Immunology 2013; 138: 93-104.
46. Bonapace L, Coissieux MM, Wyckoff J, et al. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature 2014; 515: 130-3.
47. Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 2010; 7: 448-58.